BRIEF-Johnson & Johnson Announces Approval Of Subcutaneous Rybrevant®▼ By European Commission
Johnson & Johnson -0.63%
Johnson & Johnson JNJ | 238.59 | -0.63% |
Feb 23 (Reuters) - Johnson & Johnson JNJ.N:
SUBCUTANEOUS RYBREVANT®▼ (AMIVANTAMAB) APPROVED BY EUROPEAN COMMISSION FOR EVERY-THREE-WEEK AND EVERY-FOUR-WEEK DOSING FOR PATIENTS WITH ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER
J&J: SC AMIVANTAMAB IS NOW AUTHORISED FOR USE ACROSS ALL PREVIOUSLY APPROVED INTRAVENOUS (IV) AMIVANTAMAB INDICATIONS-WEBSITE
Further company coverage: JNJ.N
